A federal judge allowed some of Eli Lilly & Co.‘s claims to proceed that allege a Texas-based compounding pharmacy violated ...

Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...

Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration's ban on the practice and luring people away from Lilly's ...

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt to ...

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly and Company and Walmart have announced a partnership to offer Zepbound single-dose vials at Walmart pharmacies. The move will start nationwide in mid-November and will have ...

BMO Capital Markets (BMO) has reiterated its Buy-equivalent outperform rating on Eli Lilly’s (LLY) stock.